About 83,893 results

ALLMedicine™ Colorectal Cancer Center

Research & Reviews  28,653 results

The Role of Fecal Fusobacterium nucleatum and pks+ Escherichia coli as Early Diagnostic...
Disease Markers; Liu K, Yang X et. al.

Dec 3rd, 2021 - Accurate analysis of intestinal microbiota will facilitate establishment of an evaluating system for assessing colorectal cancer (CRC) risk and prognosis. This study evaluates the potential role of Fusobacterium nucleatum (F. nucleatum) and Escher...

Current State of Neoadjuvant Radiotherapy for Rectal Cancer.
Clinical Colorectal Cancer; Ng SP, Ngan SY et. al.

Dec 3rd, 2021 - Colorectal cancer is the third most commonly diagnosed cancer, with rectal cancer accounting for 30% of cases. The current standard of care curative treatment for locally advanced rectal cancer is (chemo)radiotherapy followed by surgery and adjuva...

Out-of-Pocket Costs for Colonoscopy After Noninvasive Colorectal Cancer Screening Among...
JAMA Network Open; Fendrick AM, Princic N et. al.

Dec 3rd, 2021 - Out-of-Pocket Costs for Colonoscopy After Noninvasive Colorectal Cancer Screening Among US Adults With Commercial and Medicare Insurance.|2021|Fendrick AM,Princic N,Miller-Wilson LA,Wilson K,Limburg P,|

Soluble and Insoluble Dietary Fiber Consumption and Colorectal Cancer Risk: A Systemati...
Nutrition and Cancer; Arayici ME, Mert-Ozupek N et. al.

Dec 3rd, 2021 - Colorectal cancer (CRC) is the third most common cancer worldwide with a high mortality rate. Dietary fibers, both soluble and insoluble, are essential for reducing the risk of CRC. In this study, a meta-analysis was performed to examine the relat...

see more →

Guidelines  87 results

Updates on age to start and stop colorectal cancer screening: recommendations from the ...
Gastrointestinal Endoscopy; Patel SG, May FP et. al.

Nov 20th, 2021 - This document is a focused update to the 2017 colorectal cancer (CRC) screening recommendations from the U.S. Multi-Society Task Force on Colorectal Cancer, which represents the American College of Gastroenterology, the American Gastroenterologica...

Updates on Age to Start and Stop Colorectal Cancer Screening: Recommendations From the ...
Gastroenterology Patel SG, May FP et. al.

Nov 20th, 2021 - This document is a focused update to the 2017 colorectal cancer (CRC) screening recommendations from the U.S. Multi-Society Task Force on Colorectal Cancer, which represents the American College of Gastroenterology, the American Gastroenterologica...

European guidelines from the EHTG and ESCP for Lynch syndrome: an updated third edition...
The British Journal of Surgery; Seppälä TT, Latchford A et. al.

May 28th, 2021 - Lynch syndrome is the most common genetic predisposition for hereditary cancer but remains underdiagnosed. Large prospective observational studies have recently increased understanding of the effectiveness of colonoscopic surveillance and the hete...

Screening for Colorectal Cancer: US Preventive Services Task Force Recommendation State...
JAMA , Davidson KW et. al.

May 19th, 2021 - Colorectal cancer is the third leading cause of cancer death for both men and women, with an estimated 52 980 persons in the US projected to die of colorectal cancer in 2021. Colorectal cancer is most frequently diagnosed among persons aged 65 to ...

Patient and Patient Group Engagement in Cancer Clinical Trials: A Stakeholder Charter.
Current Oncology (Toronto, Ont.); Michaud S, Needham J et. al.

May 1st, 2021 - Background-to guide the implementation of patient centricity and engagement in cancer clinical trials (CTs) and to operationalize the Canadianized version of the Clinical Trials Transformation Initiative (C-CTTI) model, the development of a charte...

see more →

Drugs  109 results see all →

Clinicaltrials.gov  1,383 results

BRAF V600E-mutant Colorectal Cancer Study of Encorafenib Taken With Cetuximab Plus or Minus Chemotherapy (BREAKWATER)

Nov 26th, 2021 - The purpose of the study is to evaluate whether encorafenib plus cetuximab (EC), alone or in combination with chemotherapy, can improve clinical outcomes relative to current standard of-care chemotherapy in participants with previously untreated B...

Minimal Residual Disease Assessment in Patients With Colorectal Cancer, the MiRDA-C Study

Nov 25th, 2021 - PRIMARY OBJECTIVES: I. Demonstrate ability to monitor cancer-specific deoxyribonucleic acid (DNA), ribonucleic acid (RNA), and proteomic alterations from plasma. II. Improve detection of recurrences post completion of curative therapies through mo...

A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007)

Nov 25th, 2021 - The purpose of this study is to assess the safety and efficacy of coformulated favezelimab/pembrolizumab (MK-4280A) in participants with metastatic colorectal cancer. The study will also compare MK-4280A with the standard of care treatment of rego...

Screen to Save 2: Rural Cancer Screening Educational Intervention

Nov 24th, 2021 - The Dartmouth-Hitchcock Norris Cotton Cancer Center's Community Outreach and Engagement Team will implement Screen to Save 2 in two formats-traditional outreach using in-person fairs and an online format. The education in both formats will be base...

Anlotinib Plus Penpulimab (AK105) for Chemo-refractory Metastatic Colorectal Cancer:ALTER-C003

Nov 24th, 2021 - A single-arm, open-label clinical trial, focus on the safety and efficacy of anlotinib hydrochloride in combination with Penpulimab (AK105) in patients with Chemo-refractory Metastatic Colorectal Cancer (mCRC)

see more →

News  3,297 results

Out-of-Pocket Costs Common With Colonoscopy After Fecal Screen

Dec 2nd, 2021 - Patients needing colonoscopy after a non-invasive, stool-based test (SBT) often paid out of pocket for it, a study showed. One in six older adults who had a colonoscopy in the 6 months after some form of SBT ended up with cost-sharing, including 4...

Take action: Medicare rules

Nov 29th, 2021 - 2022 Medicare payment rules contain both good and bad news for GI. First the bad news: GIs and other specialties face millions of dollars in cuts as Medicare finalized a 3.

FDA Grants Fast Track Status to Arfolitixorin for Metastatic Colorectal Cancer

Nov 25th, 2021 - The FDA has granted a fast track designation to arfolitixorin as a potential therapeutic option for patients with metastatic colorectal cancer (mCRC), according to an announcement from Isofol Medical AB.1 Arfolitixorin is comprised of [6R]-MTHF, ...

Dr. Cohen on the Importance of Obtaining an Adequate Tissue Sample in GI Malignancies

Nov 22nd, 2021 - Steven J. Cohen, MD, medical director, Asplundh Cancer Pavilion, chief, Medical Oncology and Hematology Division, vice chair, Department of Medical Oncology, Sidney Kimmel Cancer Center, Jefferson Health – Abington, professor of medical oncology, ...

Early-Onset Colorectal Cancer: Why Is This Happening?

Nov 17th, 2021 - The following Q&A has been edited for length and clarity. In the late 2000s, Cathy Eng, MD, began noticing something strange: A growing number of patients in their 20s, 30s, and 40s with colorectal cancer (CRC), often at more advanced stages.  "CR...

see more →

Patient Education  28 results see all →